Rating Change
Cantor Fitzgerald reiterated its Overweight rating on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on November 04, 2026.
reiterateNASDAQ:SUPN
Cantor Fitzgerald Reiterates Overweight Rating on Supernus Pharmaceuticals, Inc. (SUPN)
Cantor Fitzgerald reiterated its Overweight rating on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on November 04, 2026.
At publication ·
What changed
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) · reiterate
- Firm
- Cantor Fitzgerald
- Rating
- Overweight to Overweight
- Price at event
- $27.91
- Market capitalization
- $2.6B
At a glance
Key takeaways
- Supernus Pharmaceuticals stock trades at $27.91 with a $2.6B market cap and has declined 50.2% over the past 52 weeks.
Market Context
Supernus Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $27.91 with a market capitalization of $2.6B. The stock has declined 50.2% over the past 52 weeks.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Supernus Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Supernus Pharmaceuticals, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 04, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Jul 09, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Dec 19, 2025 | Stifel | Hold | N/A |
| Oct 29, 2025 | B of A Securities | Buy | N/A |
| Oct 23, 2025 | TD Cowen | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View SUPN Stock Page
Frequently Asked Questions
What does the Overweight rating mean for SUPN?
A rating of Overweight from Cantor Fitzgerald reflects the analyst's outlook on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the SUPN forecast page.